CYRX - Cryoport, Inc.
| Previous Close | 14.69 |
| Open | 14.73 |
| Bid | 14.00 x 800 |
| Ask | 16.00 x 800 |
| Day's Range | 14.58 - 15.16 |
| 52 Week Range | 8.28 - 25.02 |
| Volume | 240,845 |
| Avg. Volume | 562,503 |
| Market Cap | 539M |
| Beta (5Y Monthly) | 0.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Cryoport Revenue Grows 81% for Third Quarter 2019
Cryoport now supports 425 clinical trials in Regenerative Medicine market Revenue from commercial therapies increased 368% over same quarter last year and 39% sequentially IRVINE, Calif. , Nov. 7, 2019 ...
- PR Newswire
Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy
- Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis - Partnership incorporates Cryoport's Cryoportal® Logistics Management Platform, SmartPak ...
- PR Newswire
Cryoport to Report Third Quarter 2019 Financial Results on November 7, 2019
IRVINE, Calif., Oct. 31, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport" or the "Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2019 on Thursday, November 7, 2019 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Third Quarter 2019 in Review", which will provide a review of Cryoport's recent financial and operational performance and a general business update, will be issued by management at 4:05 pm ET on Thursday, November 7, 2019. Cryoport management will host a conference call at 5:00 pm ET on November 7, 2019.
- PR Newswire
Cryoport Authorizes Share Repurchase Program and Presenting at Upcoming Investor Conferences
IRVINE, Calif. , Oct. 9, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the ...
- GlobeNewswire
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences industry, announce a 3-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies. This agreement with Cryoport will contribute to this, alongside other solutions including investment in the latest systems and technology, digitization of the supply chain information, and improved communications with patients and healthcare professionals. “Control and monitoring are critical because a simple temperature variation can jeopardize these cells and, ultimately, the product we supply to patients.
- PR Newswire
Cryoport Introduces Cell & Gene Industry's First Dedicated Shipper for Advanced Therapies
IRVINE, Calif., Sept. 18, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics solutions company dedicated to the life sciences industry, today announced the launch of its Advanced Therapy Shipper™ product line for the regenerative medicine market. The Advanced Therapy Shipper™ guarantees each shipper has been used only for human use and provide complete traceability of all equipment, components and commodities. The result is unmatched verification information and unmatched supply chain support for biopharma companies researching and commercializing cell and gene therapies.
- GlobeNewswire
Vineti and Cryoport Collaborate to Bring Integrated Solutions to the Global Regenerative Therapy Market
Collaboration between industry-leading supply chain orchestration (SCO) platform and the life sciences industry's most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities will bring the capabilities to support hundreds of advanced therapy clinical centers, clinical trials and commercially approved products worldwide. SAN FRANCISCO and IRVINE, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Vineti, Inc., and Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) announced a commercial partnership designed to extend end-to-end delivery of cell therapies and gene therapies to a growing number of patients as the industry continues to scale. Pairing Vineti’s supply chain orchestration (SCO) platform with Cryoport’s integrated temperature-controlled capabilities and near real-time monitoring will provide an end-to-end solution for advanced therapies, supporting the assurance of improved drug product quality and patient safety. Vineti and Cryoport together seek to leverage both of their commercial and clinical phase experiences and insights from serving biopharma customers.
- GlobeNewswire
BriaCell Appoints Richard J. Berman to Board of Directors
BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.
- PR Newswire
Cryoport Revenue Grows 83% for Second Quarter 2019
Cryoport now supports 413 clinical trials in regenerative medicine Cryoport supports the commercial launch of bluebird bio's Zynteglo™ in Europe IRVINE, Calif. , Aug. 8, 2019 /PRNewswire/ -- Cryoport, ...
- PR Newswire
Cryoport to Report Second Quarter 2019 Financial Results on August 8th, 2019
In addition to the earnings release, a document titled "Cryoport Second Quarter 2019 in Review", which will provide a review of Cryoport's recent financial and operational performance and a general business update, will be issued by management at 4:05 pm ET on Thursday, August 8. Cryoport management will host a conference call at 5:00 pm ET on August 8, 2019.
- PR Newswire
Cryoport and EVERSANA Form Strategic Alliance to Accelerate Regenerative Medicine Supply Chain
IRVINE, Calif., July 11, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) and EVERSANA™ have announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution.
- PR Newswire
Cryoport Announces Pricing of Public Offering of Common Stock
IRVINE, Calif., June 19, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (Nasdaq:CYRXW) ("Cryoport" or the "Company") today announced the pricing of its underwritten public offering of an aggregate of 3,750,000 newly issued shares of common stock at a price of $17.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock. The net proceeds to the Company from the offering of the shares are expected to be approximately $59.8 million after deducting underwriting discounts and commissions and estimated offering expenses, and assuming no exercise of the underwriters' option to purchase additional shares.
- PR Newswire
Cryoport Announces Proposed Public Offering of Common Stock
IRVINE, Calif., June 19, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (Nasdaq:CYRXW) ("Cryoport" or the "Company") today announced that it intends to offer shares of common stock in an underwritten public offering under an effective shelf registration statement on file with the Securities and Exchange Commission (the "SEC"). Cryoport also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering are to be sold by Cryoport.
- PR Newswire
Cryoport to Ring the Nasdaq Closing Bell on Monday, June 10 and Attend Jefferies 2019 Healthcare Conference June 4ᵗʰ-7ᵗʰ, 2019
IRVINE, Calif., June 5, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (Nasdaq:CYRXW) (or the "Company"), the world's leading temperature-controlled supply chain company dedicated to the life sciences industry, today announced its Chief Executive Officer, Jerrell Shelton, and other members of the management team, will ring the Nasdaq closing bell on Monday, June 10, 2019. Jerrell Shelton will be interviewed live on the "The Watch List" on the TD Ameritrade Network, on Monday, June 10, 2019 at 1:00PM Eastern Time. The Cryoport closing bell ceremony will be broadcast live starting at 3:45pm Eastern Time from the Nasdaq MarketSite Tower in New York City.
- PR Newswire
CalAmp Announces Research Collaboration with Cryoport to Develop Next Generation Condition Monitoring System
IRVINE, Calif., May 16, 2019 /PRNewswire/ -- CalAmp (CAMP), an advanced technology solutions pioneer transforming the global connected economy, today announced a strategic collaboration with Cryoport (CYRX) (Nasdaq:CYRXW), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, to develop a next generation condition monitoring system to further assure the security of global temperature controlled pharmaceutical shipments. This research and development collaboration is aimed at enhancing the protection and preservation of critical life science shipments, which demonstrates CalAmp's continued momentum in the supply chain visibility market and Cryoport's commitment to providing the most advanced best-in-class, data-driven solutions to its biopharmaceutical client base.
- PR Newswire
Cryoport Expands into Biostorage through the Acquisition of Cryogene
IRVINE, Calif., May 14, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced that it has expanded its suite of temperature-controlled solutions to include biostorage for the life sciences through its acquisition of Cryogene Partners ("Cryogene"), a Houston-based company. Cryogene operates a recently expanded 21,000 square foot state-of-the-art biostorage facility, specializing in the secure storage of biological specimens, materials and samples.
- PR Newswire
Cryoport to Host Workshop at 14th Annual World Advanced Therapies & Regenerative Medicine Congress on Wednesday, May 15th
IRVINE, Calif., May 9, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, announced today its 2nd annual workshop, titled, 'Process Considerations for Cryogenic and Regenerative Medicine Commercialization,' taking place on Wednesday, May 15, 2019 at the Business Design Centre in London, United Kingdom. The educational workshop is taking place in conjunction with the World Advanced Therapies & Regenerative Medicine Congress event and is aimed at biotechnology and pharmaceutical professionals who want to learn more about the critical considerations for the development and commercialization of vital regenerative medicine therapies.
- PR Newswire
Cryoport Revenue Grows 65% for First Quarter 2019
Commercial revenue rises to 25% of total biopharma revenue; 383 clinical trials supported IRVINE, Calif. , May 2, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" ...
- PR Newswire
Cryoport to Report First Quarter 2019 Financial Results on May 2nd, 2019
In addition to the earnings release, a document titled "Cryoport First Quarter 2019 in Review," which will provide a review of Cryoport's recent financial and operational performance and a general business update, will be issued by management at 4:05 pm ET on Thursday, May 2. Cryoport management will host a conference call at 5:00 pm ET on May 2, 2019. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company's reported results.
- PR Newswire
Celularity Selects Cryoport's Temperature Controlled Logistics Solutions
IRVINE, Calif. , April 11, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences ...
- GlobeNewswire
Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- PR Newswire
Biokin Pharmaceutical Selects Cryoport's Temperature-Controlled Solutions for its Pending Phase I and Phase II trials
CHENGDU, China and SEATTLE and IRVINE, California , March 28, 2019 /PRNewswire/ -- Biokin Pharmaceutical Co. Ltd., ("Biokin Pharma") a leading pharmaceutical company with operations in China ...
- PR Newswire
Cryoport Reports 64% Growth for Fiscal Year 2018
Cryoport now supports 357 clinical trials in the Americas and EMEA with 47 in Phase III IRVINE, Calif. , March 7, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" ...
- PR Newswire
Cryoport to Report Fourth Quarter and Fiscal Year 2018 Financial Results on March 7th, 2019
In addition to the earnings release, a document titled "Cryoport 2018 Year in Review", which will provide a review of Cryoport's recent financial and operational performance and a general business outlook, will be issued by management at 4:05 pm EST on Thursday, March 7. Cryoport management will host a conference call at 5:00 pm EST on March 7, 2019.